Navigation Links
Pharmexa A/S (DK) - Pharmexa presents data from influenza program

Summary: Pharmexa-Epimmune, the U.S.-based subsidiary of Pharmexa A/S, presents selected data from its influenza vaccine program today at the Influenza Conference entitled, "Options for the Control of Influenza VI," held in Toronto, Ontario, Canada. The data show that a "universal" vaccine designed to induce cell-mediated immune responses can protect transgenic mice against lethal experimental influenza virus challenge.

HORSOLM, Denmark, June 21, 2007-Pharmexa-Epimmune, the U.S.-based subsidiary of Pharmexa A/S, presented selected data from its influenza vaccine program today at the Influenza Conference entitled, "Options for the Control of Influenza VI," held in Toronto, Ontario, Canada. The company's "universal" vaccine strategy combines the use of multiple technologies developed over the past decade. Specifically, the experimental vaccine protected HLA transgenic mice, which are partially "humanized" against a lethal influenza virus infection.

The vaccine is designed to induce T-cell responses to highly-conserved influenza epitopes that were identified using the proprietary Epitope Identification System (EIS®). Pharmexa-Epimmune's approach is unique to the field where most vaccines are designed with the explicit goal of inducing antibody responses. The goal is to design and test a vaccine that will be protective as a "universal" influenza virus vaccine against both seasonal and pandemic viral strains.

Mark Newman, Ph.D., SVP, Global R&D Laboratories, noted: "These data are very promising and important to us for two reasons. First, we were able to demonstrate protection of the HLA transgenic mice from lethal influenza virus challenge using a vaccine designed to induce only T-cell responses. Second, we were able to demonstrate that the immune system of humans had recognized the selected vaccine epitopes as the result of past exposures to influenza virus and that the HLA transgenic mice responded in a similar manner."

Hørsholm, June 21, 2007

Jakob Schmidt Chief Executive Officer

Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525 Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558

Note to editors: Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, bone degeneration and Alzheimer's disease, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, ImmunoVaccine Technologies and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.


'"/>




Related medicine technology :

1. Pharmexa A/S (DK) - Long lasting immune response and survival to RAS vaccine
2. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
3. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
4. Data supporting three Antisoma programmes presented at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Stem cells are primitive cells found in all multi-cellular ... to differentiate into mature cell types Stem cells are ... embryonic stem cells were derived from embryos in 1981, ... culturing of embryonic stem cells from non-human primates occurred ... As a result of these discoveries, stem cells can ...
(Date:2/11/2016)... 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ), ... lives of pets, today announced the submission to FDA ... Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive ... Zimeta for the control of pyrexia (fever) in horses ... --> --> The Chemistry, Manufacturing, and ...
(Date:2/11/2016)...   Health 2.0 , the premiere showcase and ... today " 10 Year Global Retrospective ", a platform ... past ten years.   --> ... has served as the preeminent thought-leader in the health ... technologies, companies, innovators, and patient-activists through an array of ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett is ... these scholarships is to encourage applicants to pursue a degree in their field of ... parishes. , “We have available jobs in St. Landry and Evangeline Parishes that ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... cycle of pharmaceutical products, garnering increased attention from all stakeholders in the development ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... announced that nominations have closed for the ISE Southeast Awards 2016. Finalists and ... announced at the ISE® Southeast Executive Forum and Awards Gala on March 15, ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher ... Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare ... System. This will be the first Fisher House in Nevada, and will provide ...
(Date:2/12/2016)... ... February 12, 2016 , ... Erlanger Agency has announced a new partnership in ... latest campaign focuses on the fight against breast cancer, fundraising for a local woman ... here . , Carmen is a loving single mother of two boys who also ...
Breaking Medicine News(10 mins):